Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Study from a Single-Center

Abstract

Objective

Preclinical evidence and clinical trials have suggested synergistic effects of epigenetic modifiers in combination with cytotoxic agents for the treatment of leukemia. However, their efficacy in patients with relapsed/refractory acute myeloid leukemia (R/R AML) remains unclear.

Methods

Clinical data of R/R AML patients who received a CDCAG regimen (chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor) from July 1, 2018 to October 31, 2021 at our center were retrospectively assessed, and the safety and efficacy of the CDCAG regimen were evaluated. Patients were followed up until November 30, 2021, with a median follow-up of 21.6 months (95% CI: 10.0–33.2 months).

Results

A total of 67 patients were enrolled. Two patients died within 3 weeks after the initiation, and therefore only 65 patients underwent the assement for clinical response and survival. It was found that 56.9% patients achieved complete remission with a median overall survival (OS) of 9.6 months. The median OS of responders was 25.9 months, while that of non-responders was 5.0 months (P<0.0001). Patients with gene mutations had a superior overall response rate (ORR) (80.4% vs. 45.5%, P=0.043) compared to those without gene mutations. The presence of DNA methyltransferase 3 A (DNMT3A), ten-eleven translocation-2 (TET2), and isocitrate dehydrogenase 1/2 (IDH1/2) mutations did not affect the response rate (88.2% vs. 68.9%, P=0.220) and reflected a better OS (not attained vs. 9.0 months, P=0.05). The most common non-hematologic adverse events were pulmonary infection (73.1%), followed by febrile neutropenia (23.9%) and sepsis (19.4%).

Conclusions

The CDCAG regimen was effective and well-tolerated in R/R AML patients, increasing the potential for allogeneic hematopoietic stem cell transplantation. Moreover, patients with DNMT3A, TET2, and IDH1/2 mutations might benefit from this regimen.

Keywords

relapsed/refractory acute myeloid leukemia / histone deacetylase inhibitor / DNA methyltransferase inhibitor / salvage therapy

References

[1] OfranY, TallmanMS, RoweJM. How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood, 2016, 28(4): 488-496

[2] SchlenkRF, FrechP, WeberD, et al.. Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. Leukemia, 2017, 31(5): 1217-1220

[3] BoseP, VachhaniP, CortesJE. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol, 2017, 18(3): 17-46

[4] Cruz-RodriguezN, CombitaAL, ZabaletaJ. Epigenetics in Hematological Malignancies. Methods Mol Biol, 2018, 1856: 87-101

[5] LiJ, ChenY, ZhuY, et al.. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget, 2015, 6(8): 6448-6458

[6] KantarjianHM, ThomasXG, DmoszynskaA, et al.. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol, 2012, 30(21): 2670-2677

[7] HuangJ, HongM, ZhuY, et al.. Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia. Leuk Lymphoma, 2018, 59(11): 2570-2579

[8] JiangX, WangZ, DingB, et al.. The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients. Oncotarget, 2015, 6(32): 33612-33622

[9] MaoJ, LiS, ZhaoH, et al.. Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines. Am J Transl Res, 2018, 10(8): 2567-2578

[10] XuF, GuoH, ShiM, et al.. A combination of low-dose decitabine and chidamide resulted in synergistic effects on the proliferation and apoptosis of human myeloid leukerma cell lines. Am J Transl Res, 2019, 11(12): 7644-7655

[11] WangL, LuoJ, ChenG, et al.. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study. Clin Epigenetics, 2020, 12(1): 132-142

[12] ChenL, MiRH, ZhuST, et al.. Therapeutic effect of chidamide and decitabine in combiantion with CHAG priming regimen for 8 patients with relapsed/refractory acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi (Chinese), 2018, 39(7): 602-604

[13] DöhnerH, EsteyE, GrimwadeD, et al.. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017, 129(4): 424-447

[14] FergusonP, HillsRK, GrechA, et al.. An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. Haematologica, 2016, 101(11): 1351-1358

[15] MimsAS, BlumW. Progress in the problem of relapsed or refractory acute myeloid leukemia. Curr Opin Hematol, 2019, 26(2): 88-95

[16] XuJ, LvTT, ZhouXF, et al.. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study. Medicine (Baltimore), 2018, 97(39): e12102

[17] CashenAF, SchillerGJ, O’DonnellMR, et al.. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol, 2010, 28(4): 556-561

[18] CameronEE, BachmanKE, MyöhänenS, et al.. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet, 1999, 21(1): 103-107

[19] LiY, WangY, ZhouY, et al.. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells. Clin Epigenetics, 2017, 9: 83-96

[20] LiQ, HuangJC, LiaoDY, et al.. Chidamide plus decitabine synergistically induces apoptosis of acute myeloid leukemia cells by upregulating PERP. Am J Transl Res, 2020, 12(7): 3461-3475

[21] YinJ, WanCL, ZhangL, et al.. A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol, 2021, 11: 726926

[22] PicciniM, PilerciS, MerliniM, et al.. Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience. J Clin Med, 2021, 10(8): 1684-1695

[23] LouY, ShaoL, MaoL, et al.. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study. Leuk Res, 2020, 91: 106317-106320

[24] BhatnagarB, ZhaoQ, MimsAS, et al.. Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leuk Lymphoma, 2020, 61(2): 387-396

[25] AlexanderTB, LacayoNJ, ChoiJK, et al.. Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia. J Clin Oncol, 2016, 34(34): 4094-4101

[26] TholF, SchlenkRF, HeuserM, et al.. How I treat refractory and early relapsed acute myeloid leukemia. Blood, 2015, 126(3): 319-327

[27] XuQ, LiY, JingY, et al.. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen. Int J Cancer, 2020, 146(5): 1457-1467

[28] LiX, YanX, GuoW, et al.. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine. Biomed Pharmacother, 2017, 90: 699-704

[29] LunY, YangJJ, WuY. Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy. J Clin Pharm Ther, 2017, 42(6): 786-789

[30] BerguaJM, MontesinosP, Martinez-CuadrónD, et al.. A prognostic model for survival after salvage treatment with FLAG-Ida +/− gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol, 2016, 174(5): 700-710